Noetik Secures $40M Series A Funding for Advancing AI-driven Cancer Therapeutics

Noetik, a San Francisco-based AI-native biotech company, closes an oversubscribed $40 million Series A financing round to expand its spatial omics-based atlas of human cancer biology and high throughput in vivo CRISPR Perturb-Map platform, scale the training of its multi-modal cancer foundation models, and establish strategic partnerships and collaborations.